Understanding the Progression of Bone Metastases to Identify Novel Therapeutic Targets
暂无分享,去创建一个
[1] N. Melis,et al. Gallium enhances reconstructive properties of a calcium phosphate bone biomaterial , 2018, Journal of tissue engineering and regenerative medicine.
[2] Prashanth Panta,et al. MTA1 expression in human cancers - Clinical and pharmacological significance. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[3] M. Szendrői,et al. Diagnostic algorithm, prognostic factors and surgical treatment of metastatic cancer diseases of the long bones and spine , 2017, EFORT open reviews.
[4] M. Callstrom,et al. Expanding role of percutaneous ablative and consolidative treatments for musculoskeletal tumours. , 2017, Clinical radiology.
[5] J. Scimeca,et al. The multiple therapeutic applications of miRNAs for bone regenerative medicine. , 2017, Drug discovery today.
[6] A. Zygogianni,et al. The role of radiotherapy in bone metastases: A critical review of current literature , 2017, European journal of cancer care.
[7] M. Chwistek,et al. Recent advances in understanding and managing cancer pain , 2017, F1000Research.
[8] J. Laredo,et al. Vertebroplasty and interventional radiology procedures for bone metastases. , 2017, Joint, bone, spine : revue du rhumatisme.
[9] W. Fraser,et al. miR-16 is highly expressed in Paget's associated osteosarcoma. , 2017, Endocrine-related cancer.
[10] I. Berindan‐Neagoe,et al. How to Diagnose and Treat a Cancer of Unknown Primary Site. , 2017, Journal of gastrointestinal and liver diseases : JGLD.
[11] William H. Bisson,et al. Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions , 2017, Cellular and molecular gastroenterology and hepatology.
[12] C. Antonescu,et al. Integrins and Cell Metabolism: An Intimate Relationship Impacting Cancer , 2017, International journal of molecular sciences.
[13] J. Bouler,et al. Gallium, a promising candidate to disrupt the vicious cycle driving osteolytic metastases. , 2016, Biochemical pharmacology.
[14] I. Krizbai,et al. Small Vessels – Big Problems : Novel Insights into Microvascular Mechanisms of Diseases When the endothelium scores an own goal : endothelial cells actively augment metastatic extravasation through endothelial-mesenchymal transition , 2016 .
[15] M. Taketo,et al. The Role of Chemokines in Promoting Colorectal Cancer Invasion/Metastasis , 2016, International journal of molecular sciences.
[16] K. Miyazono,et al. Mechanisms of action of bone morphogenetic proteins in cancer. , 2016, Cytokine & growth factor reviews.
[17] D. Oupický,et al. Potential of CXCR4/CXCL12 Chemokine Axis in Cancer Drug Delivery , 2016, Current Pharmacology Reports.
[18] C. Van Noorden,et al. Complexity of cancer protease biology: Cathepsin K expression and function in cancer progression. , 2015, Seminars in cancer biology.
[19] E. Terpos,et al. Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma. , 2015, BoneKEy reports.
[20] S. Estrem,et al. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway , 2015, Drug design, development and therapy.
[21] Sang Hyuk Park,et al. VLA-4 and CXCR4 expression levels show contrasting prognostic impact (favorable and unfavorable, respectively) in acute myeloid leukemia , 2015, Annals of Hematology.
[22] Yihong Wan,et al. New therapeutic targets for cancer bone metastasis. , 2015, Trends in pharmacological sciences.
[23] Xiaoxiao Hu,et al. Endothelin-A receptor antagonists in prostate cancer treatment-a meta-analysis. , 2015, International journal of clinical and experimental medicine.
[24] S. Spektor,et al. Potential neurotoxic effects of polymethylmethacrylate during cranioplasty , 2015, Journal of Clinical Neuroscience.
[25] Duane D. Miller,et al. Interaction of platelet-derived autotaxin with tumor integrin αVβ3 controls metastasis of breast cancer cells to bone. , 2014, Blood.
[26] A. Sudo,et al. Anti-Tumor Necrosis Factor Therapy Inhibits Lung Metastasis in an Osteosarcoma Cell Line , 2014, Oncology.
[27] D. Heymann,et al. Preclinical evidence of potential craniofacial adverse effect of zoledronic acid in pediatric patients with bone malignancies. , 2014, Bone.
[28] M. van Driel,et al. Cancer and bone: a complex complex. , 2014, Archives of biochemistry and biophysics.
[29] Lin He,et al. miR-34a Blocks Osteoporosis and Bone Metastasis by Inhibiting Osteoclastogenesis and Tgif2 , 2014, Nature.
[30] G. Tortora,et al. CXC and CC Chemokines as Angiogenic Modulators in Nonhaematological Tumors , 2014, BioMed research international.
[31] D. Heymann,et al. Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing’s sarcoma via inhibition of cell migration , 2014, BMC Cancer.
[32] J. Bouler,et al. Is bisphosphonate therapy compromised by the emergence of adverse bone disorders? , 2014, Drug discovery today.
[33] D. Schadendorf,et al. The Impact of the Immune System on Tumor: Angiogenesis and Vascular Remodeling , 2014, Front. Oncol..
[34] F. de Marinis,et al. Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies , 2014, Therapeutic advances in medical oncology.
[35] A. Godwin,et al. Bone sialoprotein and osteopontin in bone metastasis of osteotropic cancers. , 2014, Critical reviews in oncology/hematology.
[36] T. Vanderah,et al. Cancer-induced bone pain: Mechanisms and models , 2013, Neuroscience Letters.
[37] D. Quail,et al. Microenvironmental regulation of tumor progression and metastasis , 2014 .
[38] N. Gronich,et al. Beyond aspirin—cancer prevention with statins, metformin and bisphosphonates , 2013, Nature Reviews Clinical Oncology.
[39] H. Zeng,et al. The role of neural-related factors in the metastasis of the gastrointestinal cancer. , 2013, Journal of cancer research and therapeutics.
[40] R. Wedin,et al. Insight opinion to surgically treated metastatic bone disease: Scandinavian Sarcoma Group Skeletal Metastasis Registry report of 1195 operated skeletal metastasis. , 2013, Surgical oncology.
[41] M. Heymann,et al. Current Therapeutic Strategies and Novel Approaches in Osteosarcoma , 2013, Cancers.
[42] P. Clézardin. Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activities. , 2013, BoneKEy reports.
[43] X. Yao,et al. An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions. , 2013, Asian journal of andrology.
[44] M. Suarez‐Almazor,et al. Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. , 2013, Cancer treatment reviews.
[45] B. Williams,et al. Skeletal metastasis: treatments, mouse models, and the Wnt signaling , 2013, Chinese journal of cancer.
[46] F. Mami-Chouaib,et al. Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response. , 2012, Cancer research.
[47] J. Mönkkönen,et al. In Vivo Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Trigger Vγ9Vδ2 T-cell Antitumor Cytotoxicity through ICAM-1 Engagement , 2012, Clinical Cancer Research.
[48] C. Heldin,et al. Induction of epithelial-mesenchymal transition by transforming growth factor β. , 2012, Seminars in cancer biology.
[49] A. Viola,et al. The pros and cons of chemokines in tumor immunology. , 2012, Trends in immunology.
[50] K. Gelmon,et al. Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art. , 2012, Current oncology.
[51] P. Lara,et al. Matrix metalloproteinases: potential therapy to prevent the development of second malignancies after breast radiotherapy. , 2012, Surgical oncology.
[52] J. Thariat,et al. [Improvements of ablative local treatments modify the management of the oligometastatic disease]. , 2012, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.
[53] Paul J Hertzog,et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape , 2012, Nature Medicine.
[54] G. Morgan,et al. Effects of bone-targeted agents on cancer progression and mortality. , 2012, Journal of the National Cancer Institute.
[55] G. Bernardini,et al. Chemokines and NK cells: Regulators of development, trafficking and functions , 2012, Immunology Letters.
[56] J. Cunningham,et al. Connective tissue growth factor in tumor pathogenesis , 2012, Fibrogenesis & tissue repair.
[57] T. Guise,et al. The role of TGF-β in bone metastasis: novel therapeutic perspectives. , 2012, BoneKEy reports.
[58] T. Hahn,et al. The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis , 2012, Cancer Immunology, Immunotherapy.
[59] A. Loubat,et al. Molecular effects of gallium on osteoclastic differentiation of mouse and human monocytes. , 2012, Biochemical pharmacology.
[60] D. Lyden,et al. Megakaryocytes, malignancy and bone marrow vascular niches , 2012, Journal of thrombosis and haemostasis : JTH.
[61] R. Tenaglia,et al. Reciprocal cross-talk between Prostaglandin E2 and bone in prostate cancer: a current review , 2011, Central European journal of urology.
[62] J. Kotzerke,et al. Internal radiotherapy of painful bone metastases. , 2011, Methods.
[63] J. Mönkkönen,et al. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo. , 2011, Cancer research.
[64] M. Barbagallo,et al. Physiology of the aging bone and mechanisms of action of bisphosphonates , 2011, Biogerontology.
[65] T. Guise,et al. Cancer to bone: a fatal attraction , 2011, Nature Reviews Cancer.
[66] J. V. Von Roenn,et al. American society of clinical oncology clinical practice guideline update: recommendations on the role of bone-modifying agents in metastatic breast cancer. , 2011, Journal of Oncology Practice.
[67] H. Votavova,et al. Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome , 2011, European Journal of Human Genetics.
[68] G. van der Pluijm,et al. Targeted therapy options for treatment of bone metastases; beyond bisphosphonates. , 2010, Current pharmaceutical design.
[69] Richard A. Flavell,et al. The polarization of immune cells in the tumour environment by TGFβ , 2010, Nature Reviews Immunology.
[70] Y. DeClerck,et al. Interleukin-6 in bone metastasis and cancer progression. , 2010, European journal of cancer.
[71] P. Allavena,et al. The chemokine system in cancer biology and therapy. , 2010, Cytokine & growth factor reviews.
[72] S. Koscielny,et al. Parallel progression of tumour and metastases , 2010, Nature Reviews Cancer.
[73] J. Chirgwin,et al. The critical role of the bone microenvironment in cancer metastases , 2009, Molecular and Cellular Endocrinology.
[74] B. Schaller,et al. Mechanism of bone metastasis: the role of osteoprotegerin and of the host-tissue microenvironment-related survival factors. , 2009, Cancer letters.
[75] Ajit Varki,et al. Molecular basis of metastasis. , 2009, The New England journal of medicine.
[76] Bethan Psaila,et al. The metastatic niche: adapting the foreign soil , 2009, Nature Reviews Cancer.
[77] Paula D. Bos,et al. Metastasis: from dissemination to organ-specific colonization , 2009, Nature Reviews Cancer.
[78] C. Klein,et al. Parallel progression of primary tumours and metastases , 2009, Nature Reviews Cancer.
[79] G. van der Pluijm,et al. Osteotropic cancers: from primary tumor to bone. , 2009, Cancer letters.
[80] D. Waugh,et al. The Interleukin-8 Pathway in Cancer , 2008, Clinical Cancer Research.
[81] C. Bünger,et al. Molecular treatment strategies and surgical reconstruction for metastatic bone diseases. , 2008, Cancer treatment reviews.
[82] Harold Varmus,et al. Seeding and Propagation of Untransformed Mouse Mammary Cells in the Lung , 2008, Science.
[83] J. S. San Martin,et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. , 2008, Bone.
[84] R. Weinberg,et al. Systemic Endocrine Instigation of Indolent Tumor Growth Requires Osteopontin , 2008, Cell.
[85] J. Chirgwin,et al. Molecular biology of bone metastasis. , 2008, Molecular cancer therapeutics.
[86] Michael Koutsilieris,et al. Mechanisms of bone metastasis in prostate cancer: clinical implications. , 2008, Best practice & research. Clinical endocrinology & metabolism.
[87] Tracy M Handel,et al. Chemokines and cancer: migration, intracellular signalling and intercellular communication in the microenvironment. , 2008, The Biochemical journal.
[88] R. Eils,et al. Systemic spread is an early step in breast cancer. , 2008, Cancer cell.
[89] S. Silverman,et al. Bisphosphonate‐Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[90] F. Pépin,et al. Osteoactivin Promotes Breast Cancer Metastasis to Bone , 2007, Molecular Cancer Research.
[91] D. Theodorescu,et al. The role of PTEN in prostate cancer cell tropism to the bone micro-environment. , 2007, Carcinogenesis.
[92] J. Chiras,et al. Interventional radiology in bone metastases , 2007, European journal of cancer care.
[93] R. Kaplan,et al. Bone marrow cells in the ‘pre-metastatic niche’: within bone and beyond , 2007, Cancer and Metastasis Reviews.
[94] M. Charbonneau,et al. Transforming Growth Factor β1 Induces Hypoxia-inducible Factor-1 Stabilization through Selective Inhibition of PHD2 Expression* , 2006, Journal of Biological Chemistry.
[95] T. Luger,et al. Tumor-derived matrix metalloproteinase-1 targets endothelial proteinase-activated receptor 1 promoting endothelial cell activation. , 2006, Cancer research.
[96] B. Rollins,et al. Inflammatory chemokines in cancer growth and progression. , 2006, European journal of cancer.
[97] Wei Wei,et al. Metastatic patterns in adenocarcinoma , 2006, Cancer.
[98] D. d'Ambrosio. Regulatory T cells: how do they find their space in the immunological arena? , 2006, Seminars in cancer biology.
[99] J. Bergh,et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[100] Antoinette Wetterwald,et al. Molecular and Biological Mechanisms of Bone Metastasis , 2005 .
[101] Xunbin Wei,et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment , 2005, Nature.
[102] P. Clézardin,et al. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. , 2005, Cancer research.
[103] M. Miyasaka,et al. Chemokines in tumor progression and metastasis , 2005, Cancer science.
[104] T. Yoneda,et al. Crosstalk between cancer cells and bone microenvironment in bone metastasis. , 2005, Biochemical and biophysical research communications.
[105] J. Votaw,et al. Silencing of CXCR4 blocks breast cancer metastasis. , 2005, Cancer research.
[106] L. Rosen,et al. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. , 2004, Clinical lung cancer.
[107] M. Padrines,et al. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. , 2004, Biochimica et biophysica acta.
[108] Naoto T Ueno,et al. Bone imaging in metastatic breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[109] F. Saad,et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. , 2004, Journal of the National Cancer Institute.
[110] P. Clézardin,et al. Angiostatin Inhibits Bone Metastasis Formation in Nude Mice through a Direct Anti-osteoclastic Activity* , 2003, Journal of Biological Chemistry.
[111] L. Puricelli,et al. GM-CSF secreted by murine adenocarcinoma cells modulates tumor progression and immune activity. , 2003, Oncology reports.
[112] R. Eils,et al. From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[113] I. Fidler,et al. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited , 2003, Nature Reviews Cancer.
[114] Y. Iwakura,et al. IL-1 is required for tumor invasiveness and angiogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[115] G. Mundy. Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities , 2002, Nature Reviews Cancer.
[116] C. Sotiriou,et al. Interleukins-6 and -11 expression in primary breast cancer and subsequent development of bone metastases. , 2001, Cancer letters.
[117] G. Clayman,et al. Chemokines in cancer , 2001, Expert Reviews in Molecular Medicine.
[118] P. Mantyh,et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord , 2000, Nature Medicine.
[119] G. Byrne,et al. Bone metastasis in breast cancer: the role of parathyroid hormone related protein. , 1999, Surgical oncology.
[120] C. Mackay,et al. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. , 1998, Immunology today.
[121] T. Guise,et al. Cancer and bone. , 1998, Endocrine reviews.
[122] R. Coleman. Skeletal complications of malignancy , 1997, Cancer.
[123] Jane M. Moseley,et al. Transforming growth factor beta stimulation of parathyroid hormone-related protein (PTHrP): a paracrine regulator? , 1993, Molecular and cellular endocrinology.
[124] B. Vogelstein,et al. A genetic model for colorectal tumorigenesis , 1990, Cell.
[125] S. Koscielny,et al. Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. , 1984, British Journal of Cancer.
[126] John Cairns,et al. Mutation selection and the natural history of cancer , 1975, Nature.
[127] V. P. Collins,et al. Observations on growth rates of human tumors. , 1956, The American journal of roentgenology, radium therapy, and nuclear medicine.
[128] James Ewing,et al. Neoplastic Diseases: A Treatise on Tumours , 1928, The Indian Medical Gazette.
[129] S Paget,et al. THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .
[130] P. ten Dijke,et al. Targeting TGF-β Signaling in Cancer. , 2017, Trends in cancer.
[131] U. Weidle,et al. Molecular Mechanisms of Bone Metastasis. , 2016, Cancer genomics & proteomics.
[132] M. Chaudhry,et al. Evaluation of osseous metastasis in bone scintigraphy. , 2015, Seminars in nuclear medicine.
[133] M. David,et al. Pleiotropic activity of lysophosphatidic acid in bone metastasis. , 2013, Biochimica et biophysica acta.
[134] N. Hemdan. Anti-cancer versus cancer-promoting effects of the interleukin-17-producing T helper cells. , 2013, Immunology letters.
[135] J. Thariat,et al. [Improvements of ablative local treatments modify the management of the oligometastatic disease]. , 2012, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.
[136] T. Yoneda,et al. Involvement of acidic microenvironment in the pathophysiology of cancer-associated bone pain. , 2011, Bone.
[137] T. Guise,et al. TGF-β in cancer and bone: implications for treatment of bone metastases. , 2011, Bone.
[138] T. Guise. Antitumor effects of bisphosphonates: promising preclinical evidence. , 2008, Cancer treatment reviews.
[139] C. Herzog,et al. Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma). , 2008, Expert opinion on investigational drugs.
[140] P. Camparo,et al. [Molecular aspects of prostate cancer: recent data from the literature]. , 2007, Bulletin du cancer.
[141] W. Gerald,et al. Identifying site-specific metastasis genes and functions. , 2005, Cold Spring Harbor symposia on quantitative biology.
[142] G. Dranoff,et al. Cytokines in cancer pathogenesis and cancer therapy , 2004, Nature Reviews Cancer.
[143] K. Mohammad,et al. Endothelins in bone cancer metastases. , 2004, Cancer treatment and research.
[144] G. Klein,et al. Foulds' dangerous idea revisited: the multistep development of tumors 40 years later. , 1996, Folia biologica.